KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Emergent BioSolutions (EBS) EBT Margin: 2010-2025

Historic EBT Margin for Emergent BioSolutions (EBS) over the last 16 years, with Sep 2025 value amounting to 24.92%.

  • Emergent BioSolutions' EBT Margin fell 2354.00% to 24.92% in Q3 2025 from the same period last year, while for Sep 2025 it was 13.42%, marking a year-over-year increase of 3186.00%. This contributed to the annual value of -13.69% for FY2024, which is 5599.00% up from last year.
  • Latest data reveals that Emergent BioSolutions reported EBT Margin of 24.92% as of Q3 2025, which was up 309.04% from -11.92% recorded in Q2 2025.
  • Emergent BioSolutions' EBT Margin's 5-year high stood at 48.47% during Q3 2024, with a 5-year trough of -539.60% in Q2 2024.
  • For the 3-year period, Emergent BioSolutions' EBT Margin averaged around -66.94%, with its median value being -14.18% (2024).
  • In the last 5 years, Emergent BioSolutions' EBT Margin plummeted by 46,555bps in 2024 and then soared by 52,768bps in 2025.
  • Quarterly analysis of 5 years shows Emergent BioSolutions' EBT Margin stood at 34.97% in 2021, then crashed by 5,357bps to -18.59% in 2022, then tumbled by 111bps to -19.70% in 2023, then spiked by 553bps to -14.18% in 2024, then tumbled by 2,354bps to 24.92% in 2025.
  • Its EBT Margin was 24.92% in Q3 2025, compared to -11.92% in Q2 2025 and 41.72% in Q1 2025.